Anaplastic Thyroid Cancer – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Anaplastic Thyroid Cancer – Drugs In Development, 2024 report and make more profitable business decisions.
Anaplastic thyroid cancer (ATC) is a rare and aggressive form of thyroid cancer that affects mainly older people. It grows very fast and often spreads to other parts of the body, such as the lungs, bones, and brain. It causes symptoms like a large and painful neck mass, difficulty swallowing or breathing, hoarseness, and cough. The cause of ATC is unknown, but it may be related to previous radiation exposure or other thyroid cancers. ATC is hard to treat and has a poor prognosis.
The Anaplastic Thyroid Cancer drugs in development market research report provide comprehensive information on the therapeutics under development for Anaplastic Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anaplastic Thyroid Cancer and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Anaplastic Thyroid Cancer | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 38 molecules, with 33 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Anaplastic Thyroid Cancer therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Anaplastic Thyroid Cancer pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Anaplastic Thyroid Cancer treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AffyImmune Therapeutics IncAkiram Therapeutics
AstraZeneca Plc
BeiGene Ltd
Boston Children's Hospital
Bristol-Myers Squibb Co
C4 Therapeutics Inc
Codiak BioSciences Inc
Daiichi Sankyo Co Ltd
Eisai Co Ltd
F. Hoffmann-La Roche Ltd
Faron Pharmaceuticals Oy
Genelux Corp
Hutchison MediPharma Ltd
Iovance Biotherapeutics Inc
Jiangsu Hengrui Medicine Co Ltd
Loxo Oncology Inc
Merck & Co Inc
Novartis AG
Nuvalent Inc
Ono Pharmaceutical Co Ltd
Pfizer Inc
Plexxikon Inc
Shanghai Henlius Biotech Inc
Sichuan University
Thryv Therapeutics Inc
University of Pisa
Verastem Inc
Visionary Pharmaceuticals Inc
Xencor Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Anaplastic Thyroid Cancer reports